(EMAILWIRE.COM, January 03, 2017 ) The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The growth will be fueled mainly by the uptake of new branded drugs, such as atrasentan, Optina and ranirestat. The uptake of Eylea, which will receive additional approval for diabetic retinopathy/DME, will further drive sales in the MCD market.

Scope

Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the Japan MCD market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186892

Table of Content

1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 11

2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13

3 Disease Overview 15
3.1 Etiology and Pathophysiology 17
3.1.1 Diabetic Nephropathy 17
3.1.2 Diabetic Retinopathy 19
3.1.3 Diabetic Neuropathy 20
3.2 Prognosis 21
3.3 Quality of Life 22
3.4 Symptoms 23

4 Disease Management 24
4.1 Treatment Overview 24
4.1.1 Diagnosis and Referrals 24
4.1.2 Screening 26
4.1.3 Treatment Guidelines 27
4.2 Japan 34
4.2.1 Diagnosis 34

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

Contact Information:
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results